Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 10.71 USD 0.66% Market Closed
Market Cap: 452m USD
Have any thoughts about
Urogen Pharma Ltd?
Write Note

Urogen Pharma Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Urogen Pharma Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Income from Continuing Operations
-$115.4m
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Income from Continuing Operations
-$7m
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Income from Continuing Operations
$15.7m
CAGR 3-Years
65%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Income from Continuing Operations
-$22.3m
CAGR 3-Years
-16%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Income from Continuing Operations
-$7.2m
CAGR 3-Years
28%
CAGR 5-Years
6%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Income from Continuing Operations
-â‚Ş29.2m
CAGR 3-Years
26%
CAGR 5-Years
-5%
CAGR 10-Years
-9%
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
451.9m USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
30.4 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Urogen Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
-115.4m USD

Based on the financial report for Sep 30, 2024, Urogen Pharma Ltd's Income from Continuing Operations amounts to -115.4m USD.

What is Urogen Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-5%

Over the last year, the Income from Continuing Operations growth was -10%. The average annual Income from Continuing Operations growth rates for Urogen Pharma Ltd have been -1% over the past three years , -5% over the past five years .

Back to Top